UBS Maintains a 'Buy' on Lincare Holdings (LNCR); Continues to Execute on Strategy

February 7, 2012 11:25 AM EST
Get Alerts LNCR Hot Sheet
Price: $41.49 --0%

Rating Summary:
    1 Buy, 3 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
UBS maintains a 'Buy' on Lincare Holdings (NASDAQ: LNCR) price target trimmed from $35 to $32.

UBS analyst says, "We believe LNCR’s 4Q11 results demonstrate its ongoing efforts to gain share while leveraging and diversifying its business model. In 4Q, LNCR spent ~$15 mil on a handful of acquisitions, mainly in its core respiratory area as the company consolidated markets using existing operations. LNCR also bought back $50 million in stock during 4Q ($250 mil total for 2011). We expect this strategy to persist, augmenting solid organic growth (~6% in 4Q) which is ~2x market rates due to LNCR’s national scale, differentiated referral network and service offering."

For an analyst ratings summary and ratings history on Lincare Holdings click here. For more ratings news on Lincare Holdings click here.

Shares of Lincare Holdings closed at $26.21 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change

Related Entities

UBS